Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2026
Changes to NICE’s cost effectiveness thresholds take effect
2 April 2026 - NICE has implemented new measures to evaluate the cost effectiveness of medicines, following a policy change that ...
Posted by Michael Wonder on 21 Mar 2026
Toward greater transparency at the FDA - now is the time to act
18 March 2026 - The US FDA has generally sought to uphold the highest standards of scientific rigour in its regulation ...
Posted by Michael Wonder on 20 Mar 2026
NHS spending watchdog to review evidence on Alzheimer’s treatments
20 March 2026 - England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should ...
Posted by Michael Wonder on 21 Feb 2026
Do children get priority in Australia's drug funding decisions?
20 February 2026 - In Australia, the PBAC recommends which medicines should be subsidised through the PBS. ...
Posted by Michael Wonder on 23 Jan 2026
What role does equity play in Australia’s health technology assessment processes? A review of the PBAC recommendations regarding vaccines
23 January 2026 - The Australian PBAC makes recommendations to the government on the listing of vaccines on the National Immunisation ...
Posted by Michael Wonder on 18 Dec 2025
Update from the PBAC (December 2025)
18 December 2025 - The final PBAC update for 2025 is now available. ...
Posted by Michael Wonder on 17 Dec 2025
FDA eliminates major barrier to using real world evidence in drug and device application reviews
15 December 2025 - The US FDA today removed a key limitation on the use of real world evidence used in ...
Posted by Michael Wonder on 16 Dec 2025
Updated information about PHARMAC’s priority lists as at 15 December 2025
15 December 2025 - PHARMAC’s Prioritisation Update provides the latest information about applications for medicines, vaccines, and related products that ...
Posted by Michael Wonder on 13 Dec 2025
PBAC weight loss drug decision imminent
12 December 2025 - Patients are spending as much as $5,000/year on private market GLP-1 therapies – an incoming PBAC recommendation ...
Posted by Michael Wonder on 02 Dec 2025
Korea eases path to breakthrough drugs with flexible ICER rules
1 December 2025 - The Government has unveiled a large-scale overhaul of the health insurance drug pricing system, proposing flexible ...
Posted by Michael Wonder on 01 Dec 2025
Changes to NICE’s cost effectiveness thresholds confirmed
1 December 2025 - The Government has today announced that it will increase the thresholds NICE uses in evaluations of new ...
Posted by Michael Wonder on 22 Oct 2025
Updated information about Pharmac’s priority lists (September 2025)
21 October 2025 - Pharmac’s Pūahoaho Report provides the latest information about applications for medicines, vaccines, and related products that we’ve ...
Posted by Michael Wonder on 20 Oct 2025
PHARMAC proposes greater transparency for medicine funding decisions
20 October 2025 - PHARMAC is proposing changes to bring greater transparency and clarity to how medicine funding applications are ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 09 Oct 2025
Why the Government must urgently raise the NICE cost effectiveness threshold
7 October 2025 - NICE plays an important role in determining whether new medicines will be funded for NHS patients ...